IKBKE and obesity due to melanocortin 4 receptor deficiency: Because IKKε activity has been linked to the pathology of inflammatory diseases [5, 7], a recent study identified an anti-inflammatory drug, amlexanox, as a selective inhibitor of IKKε and an approved small-molecule therapeutic presently used in the clinic to treat aphthous ulcers and in clinical trials for obesity [20].